Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase III, Multicenter Trial With Post-study Follow-up
Conditions
Interventions
AOP2014 / Pegylated-Proline-interferon alpha-2b
Surveillance
Locations
26
France
Institut Bergonié
Bordeaux, France
Centre Léon Bérard
Lyon, France
CHRU de Nancy - Hôpitaux de Brabois
Vandœuvre-lès-Nancy, France
03 Universitätsklinikum Aachen, Hämatologie/Onkologie
Aachen, Germany
18 Studienzentrum Aschaffenburg
Aschaffenburg, Germany
06 Universitätsmedizin Berlin Charite- Campus Virchow Klinikum, Klinik für Hämatologie und Onkologie
Berlin, Germany
Start Date
May 4, 2017
Primary Completion Date
January 26, 2022
Completion Date
December 12, 2022
Last Updated
March 31, 2023
NCT03852407
NCT04578847
Lead Sponsor
Philipps University Marburg
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions